Interestingly, in mutant as well as non-mutant gliomas, RIPK3 expression can additionally stratify the risk of patients: high RIPK3 expression is correlated with a worse prognosis contrasting to most other entities [8]. Here, RIPK3 is linked to central nervous system cancer.